Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

EXPLAINED: 7 | Vintage Vibes

New York Judge Denies Bristol Myers Claim To Dismiss Lawsuit Over Delayed Cancer Drug Approval: Reuters

According to a Reuters report, U.S. District Judge Jesse Furman in Manhattan refused to dismiss a $6.4 billion lawsuit accusing Bristol Myers Squibb Co (NYSE:BMY) of delaying its Breyanzi cancer drug to avoid payments to former Celgene shareholders. The judge rejected Bristol Myers' claim that it was never properly notified about its alleged default…

Benzinga

This Is What Whales Are Betting On Bristol-Myers Squibb

Someone with a lot of money to spend has taken a bullish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

3 Drug Manufacturers to Buy on the Pullback

The global pharmaceutical industry is expected to thrive with the lingering impact of COVID-19 and the evolving healthcare landscape. Given the industry’s solid prospects, the pullbacks in drug manufacturing stocks Merck & Co (MRK), Bristol-Myers Squibb (BMY), and Bayer Aktiengesellschaft (BAYRY) amid the broader market correction preset solid buying opportunity.…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Looking At Bristol-Myers Squibb's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bearish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 11 strange trades.

Benzinga

Bristol-Myers Squibb Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 25 strange trades.

Benzinga

3 Red-Hot Healthcare Stocks Ignoring the Market's Downtrend

Despite bearish market sentiment, the healthcare industry has outperformed the broader market thanks to its defensive nature. Given overwhelming demand and the need for global healthcare development, we think the stocks of quality healthcare companies Cigna (CI), Organon (OGN), and Bristol-Myers Squibb (BMY) could be solid bets now. These stocks…

StockNews.com

Bristol-Myers Squibb Whale Trades Spotted

Someone with a lot of money to spend has taken a bearish stance on Bristol-Myers Squibb (NYSE:BMY). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

3 Pharmaceutical Stocks That Look Like Huge Bargains

Increasing investments in R&D and rising expenditure on healthcare are expected to bolster the pharmaceutical sector's growth. Therefore, we think the stocks of fundamentally sound pharmaceutical companies Bristol-Myers Squibb (BMY), Bayer Aktiengesellschaft (BAYRY), and Catalyst Pharmaceuticals, Inc. (CPRX), which are currently trading at huge discounts to their peers, could be…

StockNews.com

Looking At Bristol-Myers Squibb's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bullish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb (NYSE:BMY) we detected 14 strange trades.

Benzinga

Bristol Myers' Opdivo+Yervoy Fails To Meet Survival Endpoint In Untreated Urothelial Cancer

Bristol Myers Squibb & Co's (NYSE:BMY) Phase 3 CheckMate -901 trial of Opdivo (nivolumab) plus Yervoy (ipilimumab) in urothelial carcinoma did not meet the primary endpoint of overall survival (OS) at the final analysis. The trial compared Opdivo + Yervoy to standard-of-care chemotherapy as a first-line treatment for unresectable or metastatic urothelial carcinoma…

Benzinga

BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology

BridgeBio Pharma Inc (NASDAQ:BBIO) has announced an exclusive license with Bristol Myers Squibb Co (NYSE:BMY) to develop and commercialize BBP-398, a potentially best-in-class SHP2 inhibitor, in oncology. Under the agreement terms, BridgeBio will receive an upfront payment of $90 million, up to $815 million in development, regulatory and sales milestone payments, and tiered royalties in…

Benzinga

Check Out What Whales Are Doing With BMY

Benzinga

How Does the Pharmaceutical Industry Perform During Recessions?

The Fed’s aggressive interest rate hikes and high energy prices will likely fuel recessionary conditions. Moreover, the unexpected decline in GDP in the first quarter indicates a possible economic contraction. Amid such possibilities, the pharmaceutical industry could attract investors’ attention because of the inelastic demand for its products. Today, I…

StockNews.com

4 Incredibly Cheap Large-Cap Stocks to Buy Now

The stock market has been faced with significant volatility on concerns over surging inflation, the Fed’s anticipated interest rate hikes, and continuing geopolitical instability. However, the market selloffs have created an attractive opportunity to buy quality large-cap stocks at low prices. We believe fundamentally sound large-cap stocks Bristol (BMY), Micron…

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Bristol-Myers Squibb Whale Trades For April 29

Benzinga

Bristol Myers Q1 Earnings Surpass Street Expectations, Lowers FY22 Guidance

Bristol-Myers Squibb Co (NYSE:BMY) has posted Q1 revenues of $11.65 billion, an increase of 5% Y/Y (7% constant currency), beating the consensus of $11.36 billion. Eliquis, Opdivo, cell therapy products, and Reblozyl drove sales growth. Eliquis sales increased 11% to $3.21 billion, Opdivo sales increased 12% to $1.92 billion, and Yervoy sales…

Benzinga

Bristol-Myers Squibb: Q1 Earnings Insights

Bristol-Myers Squibb (NYSE:BMY) reported its Q1 earnings results on Friday, April 29, 2022 at 06:59 AM. Here's what investors need to know about the announcement.

Benzinga

Bristol-Myers Squibb Whale Trades Spotted

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Bristol Myers' Neoadjuvant Opdivo/Chemo Therapy Yet To Reach Overall Survival Endpoint In Early-Stage Lung Cancer

Bristol Myers Squibb Co (NYSE: BMY) announced results from the Phase 3 CheckMate -816 trial in resectable non-small cell lung cancer (NSCLC).

Benzinga

Bristol Myers Squibb Scores Three Back To Back European Approvals For Opdivo In Esophageal, Urothelial Cancer

The European Commission (EC) has approved Bristol Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab) plus Yervoy (ipilimumab)

StockNews.com

3 Top-Rated Stocks for Value Investors to Consider

The recent stock market correction has created a few attractive opportunities for investors because many stocks are now trading at reasonable valuations. Thus, it could be wise now to invest in fundamentally solid stocks Bristol-Myers (BMY), McKesson (MCK), and AGCO (AGCO). These names are currently trading at discounts compared to…

Benzinga

Bristol-Myers Squibb Whale Trades Spotted

StockNews.com

3 Red-Hot Large-Cap Stocks Outpacing the S&P 500

Large-cap stocks are generally known to provide better safety to investors during periods of volatility. Therefore, we think Bristol-Myers Squibb (BMY), Vertex (VRTX), and Molina Healthcare (MOH), which have been outpacing the S&P 500, might be good investments now.

Benzinga

Check Out What Whales Are Doing With BMY

Benzinga

This Is What Whales Are Betting On Bristol-Myers Squibb

1 … 5 6 7 8

People

Dipanjan BanchurSince

722 stories

Mangeet Kaur BounsMangeet

595 stories

Jesse Furman

23 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.